Cargando…
Dual viscosity mixture vehicle for intratympanic steroid treatment modifies the ROS and inflammation related proteomes
Until recently, the most standard treatment for sensorineural or sudden hearing loss, which is caused by inner ear damage or deterioration, has been systemic oral steroid administration. In recent, intratympanic steroid injections such as dexamethasone have been used for the treatment of sudden hear...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9892634/ https://www.ncbi.nlm.nih.gov/pubmed/36744248 http://dx.doi.org/10.3389/fphar.2023.1081724 |
_version_ | 1784881362782650368 |
---|---|
author | Jung, Jin Woo Li, Hui Lee, Jung Hun Hwang, Yu-Jung Dan, Kisoon Park, Moo Kyun Han, Dohyun Suh, Myung-Whan |
author_facet | Jung, Jin Woo Li, Hui Lee, Jung Hun Hwang, Yu-Jung Dan, Kisoon Park, Moo Kyun Han, Dohyun Suh, Myung-Whan |
author_sort | Jung, Jin Woo |
collection | PubMed |
description | Until recently, the most standard treatment for sensorineural or sudden hearing loss, which is caused by inner ear damage or deterioration, has been systemic oral steroid administration. In recent, intratympanic steroid injections such as dexamethasone have been used for the treatment of sudden hearing loss as well. It is injected into the tympanic cavity through its membrane and is expected to diffuse over the round window located between the tympanic cavity and the inner ear. However, in clinical situations, the delivery time of steroids to the inner ear is shorter than 24 h, which does not allow for a sufficient therapeutic effect. Therefore, we applied a previously invented dual viscosity mixture vehicle (DVV) for intratympanic dexamethasone to a guinea pig model, which could reduce the side effects of systemic steroid administration with sufficient dwelling time for the treatment of hearing loss, and we investigated the physiological changes with a global proteomic approach. In this study, we extracted perilymph in three different conditions from guinea pigs treated with dexamethasone-embedded DVV, dexamethasone mixed in saline, and control groups to compare proteomic changes using tandem mass spectrometry analysis. After liquid chromatography coupled tandem mass spectrometry (LC-MS/MS) analysis, we first identified 46 differentially expressed proteins (DEPs) that were statistically significant after one-way ANOVA multiple-sample test. We also performed pairwise comparisons among each group to identify DEPs closely related to the treatment response of dexamethasone-embedded DVV. Gene ontology enrichment analysis showed that these DEPs were mostly related to inflammation, immune, actin remodeling, and antioxidant-related processes. As a result, the proteome changes in the DVV-treated groups revealed that most upregulated proteins activate the cell proliferation process, and downregulated proteins inhibit apoptosis and inflammatory reactions. Moreover, the reactive oxygen process was also regulated by DEPs after DVV treatment. |
format | Online Article Text |
id | pubmed-9892634 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-98926342023-02-03 Dual viscosity mixture vehicle for intratympanic steroid treatment modifies the ROS and inflammation related proteomes Jung, Jin Woo Li, Hui Lee, Jung Hun Hwang, Yu-Jung Dan, Kisoon Park, Moo Kyun Han, Dohyun Suh, Myung-Whan Front Pharmacol Pharmacology Until recently, the most standard treatment for sensorineural or sudden hearing loss, which is caused by inner ear damage or deterioration, has been systemic oral steroid administration. In recent, intratympanic steroid injections such as dexamethasone have been used for the treatment of sudden hearing loss as well. It is injected into the tympanic cavity through its membrane and is expected to diffuse over the round window located between the tympanic cavity and the inner ear. However, in clinical situations, the delivery time of steroids to the inner ear is shorter than 24 h, which does not allow for a sufficient therapeutic effect. Therefore, we applied a previously invented dual viscosity mixture vehicle (DVV) for intratympanic dexamethasone to a guinea pig model, which could reduce the side effects of systemic steroid administration with sufficient dwelling time for the treatment of hearing loss, and we investigated the physiological changes with a global proteomic approach. In this study, we extracted perilymph in three different conditions from guinea pigs treated with dexamethasone-embedded DVV, dexamethasone mixed in saline, and control groups to compare proteomic changes using tandem mass spectrometry analysis. After liquid chromatography coupled tandem mass spectrometry (LC-MS/MS) analysis, we first identified 46 differentially expressed proteins (DEPs) that were statistically significant after one-way ANOVA multiple-sample test. We also performed pairwise comparisons among each group to identify DEPs closely related to the treatment response of dexamethasone-embedded DVV. Gene ontology enrichment analysis showed that these DEPs were mostly related to inflammation, immune, actin remodeling, and antioxidant-related processes. As a result, the proteome changes in the DVV-treated groups revealed that most upregulated proteins activate the cell proliferation process, and downregulated proteins inhibit apoptosis and inflammatory reactions. Moreover, the reactive oxygen process was also regulated by DEPs after DVV treatment. Frontiers Media S.A. 2023-01-19 /pmc/articles/PMC9892634/ /pubmed/36744248 http://dx.doi.org/10.3389/fphar.2023.1081724 Text en Copyright © 2023 Jung, Li, Lee, Hwang, Dan, Park, Han and Suh. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Pharmacology Jung, Jin Woo Li, Hui Lee, Jung Hun Hwang, Yu-Jung Dan, Kisoon Park, Moo Kyun Han, Dohyun Suh, Myung-Whan Dual viscosity mixture vehicle for intratympanic steroid treatment modifies the ROS and inflammation related proteomes |
title | Dual viscosity mixture vehicle for intratympanic steroid treatment modifies the ROS and inflammation related proteomes |
title_full | Dual viscosity mixture vehicle for intratympanic steroid treatment modifies the ROS and inflammation related proteomes |
title_fullStr | Dual viscosity mixture vehicle for intratympanic steroid treatment modifies the ROS and inflammation related proteomes |
title_full_unstemmed | Dual viscosity mixture vehicle for intratympanic steroid treatment modifies the ROS and inflammation related proteomes |
title_short | Dual viscosity mixture vehicle for intratympanic steroid treatment modifies the ROS and inflammation related proteomes |
title_sort | dual viscosity mixture vehicle for intratympanic steroid treatment modifies the ros and inflammation related proteomes |
topic | Pharmacology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9892634/ https://www.ncbi.nlm.nih.gov/pubmed/36744248 http://dx.doi.org/10.3389/fphar.2023.1081724 |
work_keys_str_mv | AT jungjinwoo dualviscositymixturevehicleforintratympanicsteroidtreatmentmodifiestherosandinflammationrelatedproteomes AT lihui dualviscositymixturevehicleforintratympanicsteroidtreatmentmodifiestherosandinflammationrelatedproteomes AT leejunghun dualviscositymixturevehicleforintratympanicsteroidtreatmentmodifiestherosandinflammationrelatedproteomes AT hwangyujung dualviscositymixturevehicleforintratympanicsteroidtreatmentmodifiestherosandinflammationrelatedproteomes AT dankisoon dualviscositymixturevehicleforintratympanicsteroidtreatmentmodifiestherosandinflammationrelatedproteomes AT parkmookyun dualviscositymixturevehicleforintratympanicsteroidtreatmentmodifiestherosandinflammationrelatedproteomes AT handohyun dualviscositymixturevehicleforintratympanicsteroidtreatmentmodifiestherosandinflammationrelatedproteomes AT suhmyungwhan dualviscositymixturevehicleforintratympanicsteroidtreatmentmodifiestherosandinflammationrelatedproteomes |